Drug intelligence / Profile preview

N-myc degraders

Development stage: Preclinical
Lead developer: StemSynergy Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

StemSynergy Therapeutics is developing a program of small-molecule N-myc degraders for the treatment of N-myc-driven cancers. N-myc (MYCN) is a transcription factor often overexpressed or amplified in various aggressive cancers, including neuroblastoma and small cell lung cancer, and has historically been considered undruggable. These small molecules are designed to induce the proteasomal degradation of the N-myc protein, thereby inhibiting its oncogenic activity. The program is currently in the preclinical stage of development.

Other names: N-myc degrader program

Targets

AURKA (Aurora kinase A)MYC:Aurora kinase A protein-protein interaction interfaceMYC (MYC proto-oncogene protein)MYCN (N-myc proto-oncogene protein)

Beyond the preview

Go deeper on N-myc degraders.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-myc degraders.

Explore the full profile